This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Avastin, bevacizumab, ...
Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phe...
Orphan designation: Arsenic trioxide Treatment of acute promyelocytic leukaemia,...
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Tr...
Orphan designation: Lomitapide Treatment of familial chylomicronaemia, 17/12/201...
Orphan designation: Synthetic double-stranded siRNA oligonucleotide directed aga...
Consolidated 3-year rolling work plan for the Oncology Working Party : January 2...
Infectious Diseases Working Party (IDWP) consolidated 3-year rolling work plan 2...
Agenda of the COMP meeting 3-5 December 2024
Agenda of the COMP meeting 21-23 January 2025
Substances considered as not falling within the scope of Regulation (EC) No. 470...
Heading and text to be inserted in Section 5.1 of the SmPC
Minimum inhibitory concentration (MIC) breakpoints
Training on human variations web-based electronic application form (eAF) functio...
Demonstration of efficacy for veterinary medicinal products containing antimicro...
Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products ...
Conduct of efficacy studies for intramammary products for use in cattle - Scient...
Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Da...
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, D...